MIB: Rebound Day — Meta-AMD Deal Calms AI Fears, Novo Nordisk Enters Price War, & All Eyes Turn to Nvidia

• AMD surges 9.4% as Meta announces multiyear AI chip partnership worth up to $100B covering 6 gigawatts of AMD Instinct GPUs — deal challenges Nvidia’s data center monopoly

• Home Depot beats Q4 estimates for the first time in a year: adj. EPS $2.72 vs. $2.54 est.; raises quarterly dividend 1.3% to $2.33/share; shares +3.06%

• PayPal jumps 6.74% as Bloomberg reports Stripe is exploring an acquisition of all or parts of the payments giant after PYPL’s 46% stock-price decline

• Novo Nordisk falls another 3% as seven analysts slash price targets following Monday’s 16% CagriSema trial failure; NVO announces emergency Ozempic/Wegovy price cuts of up to 50%, dragging Eli Lilly (LLY) down 2.2%

• Consumer Confidence rises to 91.2 in February (vs. 89.0 January, 89.0 est.) — a marginal beat, but the Expectations Index remains below 80, a historically recessionary reading

• Nvidia reports Q4 FY2026 earnings after the close TOMORROW (Wednesday, Feb 25); Wall Street consensus: $65.7B revenue (+67% YoY), $1.53 EPS (+72% YoY) — the most consequential earnings print of 2026

• Bitcoin -3% today to $63,100; down 24% for February — on pace for worst monthly performance since June 2022 crypto winter; tariff uncertainty and AI jitters sapping risk appetite

1. AI Infrastructure Spending is Accelerating, Not Decelerating — Monday’s AI scare trade (Anthropic threatening IBM’s mainframe business, agentic AI disrupting SaaS) looked like a contraction narrative. Tuesday’s Meta-AMD deal reframes it: AI is redistributing value from legacy IT services to infrastructure providers. Companies with compute capacity are winning; companies depending on human labor for repetitive technical tasks are at existential risk.

2. Tariff Regime Now in a 150-Day Legal Limbo — The Supreme Court’s IEEPA tariff strike forced Trump to pivot to Section 122 authority, which caps tariffs at 15% for 150 days without Congressional extension. Businesses and multinationals face genuine uncertainty about the post-150-day landscape: no rate certainty, no supply chain finality. Markets are rallying today but have not priced this extended ambiguity.

3. GLP-1 Market Entering a Price War — Bad for Both Combatants — Novo Nordisk’s CagriSema failure handed Eli Lilly the clinical narrative, but NVO’s decision to slash Ozempic and Wegovy prices by up to 50% introduces a new threat: margin compression across the entire GLP-1 category. Lilly fell 2.2% today on those price-cut reports. The market is now asking not “who wins the trial?” but “at what price point does the winner actually earn a return?”

1. Supreme Court Kills IEEPA Tariffs; Trump Pivots to 15% Section 122 Tariffs — New 150-Day Clock Begins

The core facts:In a 6-3 ruling on February 20, the Supreme Court struck down Trump’s use of the International Emergency Economic Powers Act (IEEPA) to impose broad tariffs, holding that IEEPA does not authorize the president to levy tariffs and that taxation authority resides with Congress. Trump responded immediately — first announcing a temporary 10% global tariff, then escalating to 15% under Section 122 of the Trade Act, which grants presidents emergency authority to impose up to 15% tariffs for up to 150 days to address a balance-of-payments crisis. The new 15% global tariff took effect this week, running concurrent with existing Section 232 (national security) and Section 301 (unfair trade practices) tariffs, which were not affected by the SCOTUS ruling.

Why it matters:The ruling eliminates IEEPA as a blanket tariff weapon but does not end Trump’s trade agenda — it redirects it. Section 122 tariffs expire in 150 days unless Congress acts to extend or modify them, creating a hard deadline that will dominate trade policy headlines through summer 2026. For multinationals, CFOs cannot make long-term supply chain decisions on a 150-day framework. The EU has already warned it will respond. Bond markets, which rallied on the SCOTUS ruling anticipating tariff relief, have largely given back those gains as the scope of Trump’s alternative authority became clear. Monday’s 800-point Dow drop incorporated the new tariff announcement; Tuesday’s rebound reflects markets parsing the legal limits, not celebrating tariff removal.

What to watch:Monitor Congressional votes on extending Section 122 authority beyond the 150-day window (deadline ~mid-July 2026) and any EU/China retaliatory measures announced in the next 30 days. The PIIE and Tax Foundation have both published legal analyses questioning whether Section 122 tariffs will survive challenge — watch for additional litigation filings.

2. Meta-AMD Landmark Deal: Up to $100B AI Chip Partnership for 6 Gigawatts of GPU Capacity — AMD +9.4%

The core facts:Meta Platforms and AMD announced a multiyear strategic partnership to deploy up to 6 gigawatts of AMD Instinct GPUs across Meta’s AI data centers, with the first wave deploying custom AMD Instinct MI450-based GPUs (with AMD’s 6th Gen EPYC “Venice” CPUs) beginning in the second half of 2026. The deal is valued at $60-$100 billion depending on build-out pace, with Meta receiving a performance-based warrant for up to 160 million AMD shares vesting as purchase milestones are hit. Critically, this comes days after Meta also announced a massive expanded partnership with Nvidia — meaning Meta is deliberately building a multi-vendor AI chip supply chain.

Why it matters:This deal shatters the market assumption that Nvidia holds an unassailable monopoly on AI training infrastructure. Meta’s decision to run parallel mega-deals with both AMD and Nvidia simultaneously signals: (1) hyperscalers have sufficient demand to absorb multiple competing architectures, (2) AMD’s Instinct GPU line is now credible enough for production-scale deployment at the world’s largest social media company, and (3) Meta’s “personal superintelligence” ambition requires so much compute that no single vendor can supply it. AMD shares jumped 9.4%, adding approximately $18 billion in market cap. The deal also provides a meaningful counternarrative to Monday’s AI fear trade: AI is not decelerating — it is expanding.

What to watch:Watch AMD’s Q1 2026 earnings guidance (next report due ~late April) for evidence that the MI450 ramp is tracking to plan. Also monitor Intel’s response — if AMD can win a deal of this scale, Intel’s GPU aspirations become more relevant.

3. Anthropic’s Claude Code Threatens Legacy IT Dominance — IBM Loses 13% Monday in Steepest Drop Since 2000

The core facts:On Monday, Anthropic released a “Code Modernization Playbook” for Claude Code, its AI coding tool, detailing its ability to automate COBOL legacy code analysis — mapping dependencies, documenting workflows, and identifying migration risks across thousands of lines of code in hours rather than the months it takes human teams. The announcement directly targeted the business model of IBM, which generates significant revenue from COBOL-based mainframe services for the financial sector. IBM’s stock collapsed 13.2% Monday — its worst single-day drop since October 2000 — shedding 27% of its market value for February. The AI disruption wave also pulled down Microsoft (-3%), CrowdStrike (-10%), and other enterprise software names on fears that agentic AI will automate white-collar IT work at scale.

Why it matters:An estimated 95% of US ATM transactions run on COBOL. For decades, the cost of understanding and rewriting legacy COBOL systems exceeded the cost of maintaining them — that economic equation has now been inverted by AI. IBM’s mainframe division was considered a durable, near-impossible-to-disrupt business with multi-decade contracted revenue. The market’s 13% verdict in a single day signals that institutional investors now believe this moat has cracked. The broader “AI scare trade” — selling any company whose human workforce is a primary cost center or competitive advantage — is accelerating. Tuesday’s partial recovery in software stocks is a bounce, not a reversal of this structural trend.

What to watch:Monitor IBM’s next earnings call for management commentary on COBOL modernization revenue exposure. Watch for enterprise IT services peer reactions (Accenture, Cognizant, Infosys) — if they follow IBM lower on similar AI displacement fears, the disruption trade is broadening from point-specific to sector-wide.

4. Novo Nordisk’s CagriSema Fails to Beat Eli Lilly’s Zepbound in Head-to-Head Trial — Stock Down 16% Monday, Another 3% Tuesday

The core facts:Novo Nordisk announced Sunday that CagriSema, its next-generation dual-agonist combination drug and the centerpiece of its competitive strategy, failed to achieve non-inferiority versus Eli Lilly’s tirzepatide (Zepbound) in a landmark head-to-head trial. Patients on CagriSema achieved 20.2% weight loss after 84 weeks versus 23.6% for tirzepatide — a 3.4 percentage point shortfall that is both clinically and commercially meaningful. NVO fell 16.4% on Monday to multi-year lows not seen since June 2021, then fell another 3% on Tuesday as seven analysts issued downgrades and slashed price targets. At least one analyst noted CagriSema revenue could have accounted for 15-25% of Novo’s 2030 revenue projections, creating a strategic void that may require $35 billion or more in M&A to fill.

Why it matters:This is Novo Nordisk’s third major pipeline disappointment in a year on its obesity portfolio. The clinical verdict, combined with Tuesday’s news that NVO is planning emergency price cuts of up to 50% on Ozempic and Wegovy, suggests the company is responding to competitive pressure with a defensive pricing strategy rather than an offensive pipeline. For healthcare portfolio managers, the story has flipped from “GLP-1 duopoly” to “Lilly dominance.” NVO’s 60% decline over the past 12 months has wiped hundreds of billions in market cap. The company represents a cautionary tale about what happens when a pipeline story at premium valuation collides with clinical disappointment.

What to watch:Watch Novo Nordisk’s Q1 2026 earnings (typically April/May) for updated guidance and M&A announcements. Monitor any FDA regulatory decisions on CagriSema for narrower indications, and track Lilly’s formulary penetration metrics for Zepbound as payers update coverage decisions.

5. February Consumer Confidence Beats at 91.2 — But Future Expectations Index Still Below the Recessionary Threshold of 80

The core facts:The Conference Board’s Consumer Confidence Index rose 2.2 points in February to 91.2 (1985=100), beating the 89.0 consensus estimate and reversing January’s collapse, which was one of the steepest single-month declines in years. The beat contributed to Tuesday’s market rally. However, the internal data is more nuanced: the Present Situation Index (measuring current economic conditions) fell 1.8 points to 120.0, while the Expectations Index (measuring 6-month forward outlook) improved 4.8 points to 72.0. The labor market differential (jobs “plentiful” minus “hard to get”) rose 0.6 points to +7.4%. Consumers cited prices, inflation, tariffs, and politics as top concerns — the first meaningful mention of trade policy in several months.

Why it matters:A headline beat looked good, but the Expectations Index at 72.0 is below the 80-point level that historically signals recession risk. When consumers feel good about today but pessimistic about tomorrow, spending plans shift defensively — services spending softened while big-ticket durable goods (cars, appliances) rose, a pattern consistent with “spend now before tariffs hit” behavior rather than genuine confidence in the outlook. For equity markets, this print provided relief that consumer psyche hadn’t collapsed; for bond markets and Fed watchers, it confirms the FOMC has no reason to cut rates imminently while trade policy remains inflationary.

What to watch:Watch the March Conference Board release (due late March) to see if the February bounce sustains or reverses — if tariffs drive prices higher in March, the Expectations Index could fall back below 70. Also monitor the University of Michigan preliminary reading (typically 2nd Friday of the month) for a corroborating signal.

6. PayPal Draws Takeover Interest From Stripe and Others After 46% Stock Decline — PYPL +6.74%

The core facts:Bloomberg reported that PayPal has fielded unsolicited takeover interest from multiple parties following the stock’s 46% decline, with Stripe — the private payments processor valued at $159 billion — exploring an acquisition of all or parts of PayPal. PayPal’s current market cap of approximately $44 billion would make this one of the largest fintech transactions in history. Other potential suitors are reportedly interested in specific PayPal assets rather than the whole company. PYPL jumped 6.74% to $47.02 on unusually high volume — 57.8 million shares, roughly 187% of the 3-month average. Mizuho reiterated its rating, noting the takeover reports add an optionality premium to the shares.

Why it matters:PayPal’s 46% decline over 18 months has created a rare situation: a company processing approximately $1.5 trillion in annual payment volume trading at a single-digit forward P/E. That valuation gap is what is attracting strategic buyers. A Stripe-PayPal combination would create a payments juggernaut controlling significant portions of both consumer (PayPal) and business (Stripe) payments infrastructure. However, deal risk is substantial: antitrust review would be intense, Stripe is private and would need to raise enormous amounts of capital, and PayPal’s board has not confirmed it is for sale. The 6.74% move prices in optionality, not certainty.

What to watch:Watch for formal offer announcements or SEC 13D filings indicating a stake has been taken in PYPL. Any confirmation from PayPal’s board that it is engaging with parties would likely push the stock significantly higher; denial or silence would likely see the premium evaporate.

7. CrowdStrike Down 26.5% Since January 27 as Agentic AI Threatens to Commoditize Cybersecurity Detection

The core facts:CrowdStrike (CRWD) has declined 26.5% since January 27, falling from $476.66 to $350.33 as of Tuesday’s close — a loss of approximately $55 billion in market capitalization in less than a month. The slide accelerated on Monday when Anthropic’s Claude Code announcement raised fears that AI would automate security threat detection and code analysis. Tuesday brought no relief: CrowdStrike released its 2026 Global Threat Report, which highlighted that average attacker “breakout time” has fallen to a record-low 29 minutes, a finding that ironically underscores the urgency of automated defense — but markets read it as evidence that the security landscape is deteriorating faster than traditional tools can adapt. Peer stocks Palo Alto Networks and Zscaler also declined sharply earlier this week.

Why it matters:CrowdStrike trades at a significant premium to the cybersecurity sector based on its AI-native Falcon platform and best-in-breed endpoint detection. If agentic AI can perform threat detection and response at human or better accuracy, the proprietary AI advantage that justified that premium erodes. The 26.5% decline represents a partial repricing of that premium, not a full reset — CRWD still commands a high growth multiple. The deeper question for portfolio managers: is this a buying opportunity in a premier security platform temporarily mispriced by fear, or the beginning of a structural de-rating of endpoint-focused security vendors?

What to watch:CrowdStrike’s next earnings report (due late May/early June) will be critical — watch ARR growth trajectory and net new customer adds for signs that AI disruption fears are affecting deal wins. Any major enterprise contract announcement in the interim could serve as a sentiment reset.

8. Novo Nordisk Plans Emergency 50% Price Cuts on Ozempic and Wegovy — GLP-1 Margin War Begins, Lilly Falls 2.2%

The core facts:The Wall Street Journal reported Tuesday that Novo Nordisk is planning to slash US list prices on its blockbuster GLP-1 drugs Ozempic (semaglutide, diabetes) and Wegovy (semaglutide, obesity) by up to 50% as it grapples with the dual pressure of CagriSema’s clinical failure and accelerating market share losses to Eli Lilly’s tirzepatide. The price cuts are part of a defensive strategy to protect volume and formulary positioning with insurance payers. The announcement sent Eli Lilly (LLY) shares down 2.2% on fears that competitive pricing pressure could force Lilly to respond in kind, compressing margins across the entire GLP-1 category — even for the clinical leader.

Why it matters:GLP-1 drugs have been one of the most profitable categories in pharmaceutical history, commanding premium pricing with minimal competitive pushback. A 50% price cut by the second-largest player fundamentally changes the economics of the market for both companies and downstream insurers. Payers who have been resisting broad Wegovy/Zepbound coverage on cost grounds may accelerate formulary inclusion at reduced prices — potentially expanding the market but at lower per-unit economics. For Lilly, this is a double-edged sword: more patients could access Zepbound, but at negotiated prices significantly below current list.

What to watch:Watch Eli Lilly’s pricing response and any formulary announcements from major pharmacy benefit managers (CVS Caremark, Express Scripts) in the next 30-60 days. A tiered pricing model where Wegovy/Ozempic are offered at 50% discount could fundamentally reshape how insurers cover the entire GLP-1 class.

9. Bitcoin -24% in February: On Track for Worst Monthly Performance Since the June 2022 Crypto Winter

The core facts:Bitcoin fell another 3% Tuesday to $63,100, bringing February’s decline to approximately 24% — putting it on pace for its worst monthly performance since June 2022, when the crypto market collapsed during the post-peak “crypto winter.” BTC dipped below $63,000 during Asian trading hours before partially recovering. The cryptocurrency has been under sustained pressure from the combined headwinds of Trump’s tariff shock (which has dampened risk appetite broadly), AI disruption fears displacing speculative capital, and technical selling as key support levels at $65K were decisively breached. Analysts note the $60,000-$63,000 zone as the next critical support band.

Why it matters:Bitcoin’s February performance is a useful risk-sentiment barometer. When BTC and equities sell off together (as they have this month), it suggests genuine deleveraging rather than a rotation from risk-to-safe-haven assets. The crypto selloff is also relevant for companies with BTC treasury strategies (MicroStrategy, etc.) and for crypto-adjacent equities (Coinbase, crypto miners) which have underperformed broadly. The $60K support level is widely watched — a break below it would likely trigger further forced selling and amplify equity market volatility given the interconnected positioning of leveraged crypto traders.

What to watch:Monitor the $60,000 support level as a potential capitulation trigger for leveraged BTC positions. If BTC holds here and equities continue to recover, a relief bounce toward $70K is possible. Watch for any US regulatory news that could catalyze a directional move.

10. Gold Retreats 2% to $5,147 from Monday’s Tariff-Shock High of $5,254 — Safe-Haven Demand Persists Despite Equity Rebound

The core facts:Gold fell 2% on Tuesday to $5,147/oz from Monday’s tariff-shock high of $5,254 — a partial unwinding of the safe-haven bid as equities recovered. However, gold remains up significantly for the year, having reached an all-time high of $5,589.38 on January 28, 2026, before the current pullback. The precious metal rose 3.4% on Monday alone as investors scrambled for protection following the SCOTUS tariff ruling and its aftermath. Tuesday’s equity rebound partially offset that flight, but gold’s resilience above $5,100 signals that institutional investors are not fully reversing their defensive positioning. Geopolitical tensions with Iran and ongoing tariff uncertainty are keeping a floor under gold demand.

Why it matters:Gold trading above $5,000 simultaneously with equity markets recovering is unusual and signals that institutional allocators are running dual positioning — long equities for the AI upside, long gold for the tariff and geopolitical downside. This bifurcated positioning is consistent with a market pricing genuine macro uncertainty rather than a clean bull or bear case. For portfolio managers, the gold signal suggests the smart money does not believe the Tuesday equity rebound resolves the underlying macro risks. The tariff overhang, SCOTUS legal uncertainty, and Nvidia earnings binary event are keeping hedges in place.

What to watch:Watch the $5,100/oz support level — if gold breaks below it amid a sustained equity rally, it would signal the market is pricing genuine resolution of tariff risk rather than just a tactical bounce. A gold move back above $5,250 would confirm that macro hedging is intensifying.

11. Home Depot (HD): +3.06% | First Earnings Beat in Four Quarters as Housing Recovery Gains Traction

The Numbers:Released BMO. Q4 FY2025: Revenue $38.2B (vs. prior year’s $38.7B which included a 14th fiscal week worth ~$2.5B — on an apples-to-apples basis, underlying sales improved). Adj. EPS $2.72 vs. $2.54 consensus estimate. Comparable US sales +0.3% (first positive comp in four quarters). Full-year FY2025: Revenue $164.7B (+3.2% YoY). Quarterly dividend raised 1.3% to $2.33/share. FY2026 guidance: Total sales growth +2.5% to +4.5%; comparable sales flat to +2.0%; EPS growth flat to +4.0%.

The Win:HD beat EPS estimates for the first time in a year after missing the prior three quarters — a streak that had been a persistent drag on investor confidence. The beat was driven by improving big-ticket project spending (kitchen and bath remodels, flooring), which had been depressed by high mortgage rates limiting housing turnover. A modest improvement in housing activity, combined with pent-up demand from homeowners who have been deferring projects, drove the comp turnaround. The 1.3% dividend hike signals management confidence in the forward trajectory.

The Ripple:Lowe’s (LOW) shares gained sympathetically, up approximately 1.5%, as the result signals the home improvement category is stabilizing. Housing-adjacent names (Sherwin-Williams, Stanley Black & Decker) also saw modest positive moves. The print reinforces that the consumer, while cautious on future expectations, is still spending on the home — a constructive signal for consumer discretionary broadly.

What It Means:Home Depot’s result suggests the housing-related spending cycle is bottoming after two years of interest-rate-driven weakness. If mortgage rates decline modestly in 2026 as the market expects, comparable sales growth could accelerate meaningfully from the current +0.3% — making HD’s FY2026 guidance potentially conservative.

What to watch:Watch HD’s Q1 FY2026 report (due ~May 2026) for evidence that the comparable sales recovery is accelerating, particularly big-ticket project spending. Also monitor the 30-year fixed mortgage rate — each 25 bps decline historically adds approximately 0.4-0.6% to HD’s comparable sales growth.

Conference Board Consumer Confidence: February Reading Rises to 91.2, But Future Outlook Remains Recessionary (Conference Board, Feb 24, 2026)

What they’re saying:The Conference Board reported that consumer confidence rose 2.2 points in February to 91.2, modestly beating the 89.0 consensus. The present situation index fell 1.8 points to 120.0, while the expectations index (6-month forward outlook) improved 4.8 points to 72.0. However, the expectations index remains below 80 — the historical level the Conference Board identifies as consistent with recessionary conditions ahead. Mentions of tariffs, trade policy, and politics rose meaningfully in February’s survey comments for the first time in months.

The context:The headline beat is encouraging but the underlying split — strong present conditions, weak future expectations — is a warning flag. January 2026 was one of the steepest single-month confidence declines in years, so the February recovery may reflect relief rather than genuine optimism. The 72.0 expectations reading has historically preceded slowdowns within 6-9 months. With tariff uncertainty now entering consumer consciousness, a further deterioration in the March reading is plausible.

What to watch:The University of Michigan preliminary consumer sentiment reading (due second Friday of March) will provide early triangulation on whether February’s Conference Board bounce is sustained. Watch specifically the inflation expectations component — if 1-year inflation expectations rise above 4%, it will reinforce the stagflationary scenario.

Atlanta Fed GDPNow: Q1 2026 Tracking at 3.1% — Down from 4.2% in Early February (Atlanta Fed, Feb 20, 2026)

What they’re saying:The Atlanta Federal Reserve’s GDPNow model estimated Q1 2026 real GDP growth at 3.1% as of February 20, down from a peak tracking estimate of 4.2% earlier in February. The slowdown reflects incoming data on consumer spending, trade flows, and inventory levels that have been softer than initially projected. Personal consumption expenditures are still the primary driver of growth, contributing approximately 2.9 percentage points to the overall estimate.

The context:The decline from 4.2% to 3.1% in less than three weeks is notable. While 3.1% would still represent solid above-trend growth, the directional deterioration — combined with tariff headwinds that have not yet fully registered in consumption data — raises the possibility that the Q1 GDPNow estimate will continue to soften as February trade and spending data are incorporated. The Fed’s FOMC, currently holding the target rate at 3.50%-3.75%, is watching these estimates closely as it assesses the growth/inflation tradeoff.

What to watch:The next GDPNow update (due later this week following Thursday’s jobless claims data) will incorporate February trade and labor data. Watch for the estimate to fall further toward 2.5% as tariff-related import front-running in January reverses in February — a pattern consistent with post-tariff-announcement consumption pullbacks.

Federal Layoffs at Pandemic-Era Levels: DOGE Cuts Accelerate in February, Government Leading All Sectors (Challenger Gray, February 2026)

What they’re saying:US employers announced 172,017 total job cuts in February — the highest February total since 2009 — with the federal government leading all sectors at 62,242 announced layoffs across 17 agencies, driven by DOGE’s mass dismissal and contract cancellation campaign. The federal cuts represented a 245% jump from January. Beyond government, retailers cut approximately 39,000 jobs and technology companies cut 14,554 positions. Some analyses project DOGE actions could result in as many as 500,000 total federal layoffs by year-end, including contract workers and indirect employment.

The context:The federal government shed approximately 300,000 workers in 2025 and another 33,000-34,000 in January 2026 before February’s acceleration. Most impacted agencies include USAID (largely shuttered), CFPB, HHS, and the Department of Education. The knock-on economic effects are beginning to register in regional economies where federal employment is concentrated (DC metro, Northern Virginia, Maryland). Moody’s puts 2026 recession probability at approximately 42%, citing the stacking of tariffs, deportation-related labor supply reduction, and federal spending cuts as mutually reinforcing headwinds.

What to watch:Thursday’s initial jobless claims report (week ending Feb 21) will be the first major labor market data point incorporating some of the February DOGE cuts. Watch for an unusual spike in government worker claims filings, which would confirm the labor market disruption is reaching macro-relevant scale. The February BLS nonfarm payrolls report (due early March) is the first major data point that will quantify the cumulative DOGE employment impact.

Moody’s Raises 2026 Recession Probability to 42% as Policy Headwinds Stack Up (Moody’s Analytics, February 2026)

What they’re saying:Moody’s Analytics puts the probability of a US recession in 2026 at approximately 42%, citing the simultaneous application of four distinct contractionary policy forces: tariffs (reducing real household purchasing power), mass deportations (reducing labor supply in construction, agriculture, and services), federal spending cuts via DOGE (removing government demand from the economy), and persistently tight monetary policy (Fed funds at 3.50%-3.75%). The firm’s base case remains a soft landing with growth slowing to approximately 1.5-2.0%, but the distribution of outcomes has shifted markedly toward the downside. Some private forecasters have raised recession odds even higher, with one noted at 33% and others at 40%+.

The context:A 42% recession probability is not a prediction of recession — it means Moody’s believes a downturn is roughly as likely as a coin landing on heads. What makes this elevated reading significant is the reinforcing nature of the risk factors: tariffs reduce purchasing power at the same time DOGE cuts reduce government services and employment, layering deflationary (job losses) on inflationary (tariff-driven price increases) pressures simultaneously. This stagflationary mix is particularly difficult for the Fed to navigate.

What to watch:Watch the February BLS nonfarm payrolls report (expected early March) and the March Conference Board consumer confidence reading for early signs that recession risks are materializing. The NY Fed recession probability model (based on the yield curve) and its next monthly update are also key inputs to track.

• Wednesday, Feb 25 — Nvidia (NVDA) Q4 FY2026 Earnings (AMC): The most consequential earnings release of 2026. Wall Street expects $65.7B revenue and $1.53 EPS; guidance for Q1 FY2027 and full-year commentary on Blackwell GPU demand, China exposure, and agentic AI spending will set the tone for the entire AI sector through Q2. A strong beat + raised guidance could reset the AI bull case after this week’s disruption-trade selloff; a miss or cautious guidance could extend the selloff and weigh on the Nasdaq.

• Thursday, Feb 26 — Initial Jobless Claims (Week Ending Feb 21): First major labor market data point that may begin to capture the February DOGE federal layoff acceleration. A spike in government worker claims filings would signal the DOGE cuts are reaching macro-relevant scale and would increase recession probability estimates.

• Friday, Feb 27 — Producer Price Index (PPI and Core PPI, m/m): Inflation data that will inform whether tariff-driven price pressures are already flowing through producer channels. A hotter-than-expected reading would reinforce the stagflationary scenario and reduce the probability of Fed rate cuts in 2026.

• Ongoing This Week — Tariff Litigation: Watch for additional legal challenges to Trump’s Section 122 tariffs. Legal experts at PIIE and the Tax Foundation have flagged potential weaknesses in the balance-of-payments justification. Any expedited court filing could move markets as quickly as the original SCOTUS ruling did last Friday.

1. Will Nvidia’s Q4 FY2026 results and guidance on Wednesday, Feb 25, be strong enough to restore confidence in the AI spending cycle — or will any signs of Blackwell demand deceleration or cautious China commentary trigger a broad Nasdaq selloff that undoes Tuesday’s AI relief rally?

2. Will the Supreme Court’s IEEPA tariff ruling trigger additional legal challenges to Trump’s Section 122 authority before the 150-day clock expires, and how will trading partners (particularly the EU) respond with retaliatory measures that could force further market repricing of global growth?

3. Does the GLP-1 drug market enter a structural price war — with Novo Nordisk’s reported 50% Ozempic/Wegovy price cuts forcing Eli Lilly’s hand — and if so, what does margin compression across the entire obesity drug category mean for healthcare sector earnings estimates for 2026 and 2027?